Dominik Hotter

Boehringer Ingelheim (Germany)

Papers

1

Total Citations

30

H-Index

1

About

Dominik Hotter is a virologist and biotechnologist whose research focuses on the development and characterization of virus-based therapeutics, particularly in the areas of viral vector production, infectivity assays, and quality control. His most notable contribution is the creation of an automated, label-free TCID50 assay, which provides a high-throughput, reproducible method for determining the infectious titer of viral therapeutics—a critical step in vaccine and gene therapy manufacturing. This work, published in 2021 and cited over 30 times, addresses a key bottleneck in the field by replacing labor-intensive, subjective manual counting with a standardized, image-based approach. Hotter’s research bridges virology and process analytics, enabling faster and more reliable potency testing for clinical-grade viral products. His achievements include advancing the application of label-free imaging technologies to virology, thereby improving the scalability and regulatory compliance of virus production. By streamlining titer determination, Hotter’s work supports the efficient development of oncolytic viruses, viral vectors for gene therapy, and vaccines, making him a valuable contributor to the translational pipeline of virus-based medicines.

Research Focus

Key Achievements

1
H-Index
1
Papers
30
Total Citations
30
Avg Citations/Paper
🏆 Most Cited Paper
Automated, label-free TCID50 assay to determine the infectious titer of virus-based therapeutics
30 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 4
🏛 Institutions: Boehringer Ingelheim (Germany)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago